Macro­Gen­ics chief Scott Koenig de­tails the up­beat can­cer drug da­ta from 2 pro­grams that drove a big spike in their share price

Macro­Gen­ics $MGNX dropped their AS­CO ab­stracts on 2 key drug pro­grams on Wednes­day evening, high­light­ing some ad­di­tion­al de­tails on da­ta that spurred their share price a cou­ple of days ago.

The sur­prise da­ta that cap­tured in­vestors’ at­ten­tion in­clude the news that 43% — 6 of 14 — of pa­tients with ad­vanced HER2 tu­mors demon­strat­ed an ob­jec­tive re­sponse to a com­bi­na­tion of mar­ge­tux­imab and MGD013 with 4 con­firmed re­spons­es and ev­i­dence of tu­mor shrink­age that could dri­ve that re­sponse rate even high­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER